//
Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
Sex- and Race-Related Differences in Characteristics and Outcomes of Hospitalizations for Heart Failure With Preserved Ejection Fraction
Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial
Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes
Angiotensin–neprilysin inhibition versus enalapril in heart failure
Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients
The spectrum of heart failure: value of left ventricular ejection fraction and its moving trajectories
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction